Journal of Dermatology最新文献

{"title":"Author Guidelines","authors":"","doi":"10.1111/1346-8138.17729","DOIUrl":"https://doi.org/10.1111/1346-8138.17729","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"e326-e329"},"PeriodicalIF":2.9,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17729","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143793356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial","authors":"Xingqi Zhang,&nbsp;Yanting Ye,&nbsp;Weiling Sun,&nbsp;Youyu Sheng,&nbsp;Misaki Kinoshita-Ise,&nbsp;Taisuke Ito,&nbsp;Cheng-Che Lan,&nbsp;Ohsang Kwon,&nbsp;Gregor Schaefer,&nbsp;Robert Wolk,&nbsp;Shasha Hu,&nbsp;Qiankun Sun,&nbsp;Yimeng Shen,&nbsp;Masayo Sakaki-Yumoto","doi":"10.1111/1346-8138.17539","DOIUrl":"10.1111/1346-8138.17539","url":null,"abstract":"<p>This subgroup analysis of the ALLEGRO phase 2b/3 study (NCT3732807) assessed the efficacy and safety of multiple doses of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in Asian patients with alopecia areata (AA). Patients aged ≥12 years with AA and ≥50% scalp hair loss received once-daily ritlecitinib 50 or 30 mg (with or without 4-week 200-mg loading dose [“200/50” or “200/30”]) or 10 mg or placebo for 24 weeks, followed by a 24-week extension, in which patients initially assigned to placebo switched to 200/50 or 50 mg. In this subgroup analysis, Asian patients with response based on achieving a Severity of Alopecia Tool (SALT) score ≤20, SALT ≤10, ≥2-grade improvement or normal score on the eyebrow assessment (EBA) scale, and ≥2-grade improvement or normal score on the eyelash assessment (ELA) scale were evaluated through week 48. Safety was monitored throughout. In total, 186 Asian patients were randomized to ritlecitinib 200/50 mg (<i>n</i> = 33), 200/30 mg (<i>n</i> = 28), 50 mg (<i>n</i> = 43), 30 mg (<i>n</i> = 34), 10 mg (<i>n</i> = 17), placebo to 200/50 mg (<i>n</i> = 14), or placebo to 50 mg (<i>n</i> = 17). The proportions of patients treated with ritlecitinib ≥30 mg achieving a SALT score ≤20 response were 9.1%–36.4% at week 24 vs 0% for the 10-mg group and 3.2% for placebo. At week 48, 26.5%–55.6% of patients treated with ritlecitinib ≥30 mg achieved a SALT ≤20 response. At week 48, the proportions of patients treated with ritlecitinib ≥30 mg with EBA response were 41.9%–71.1% and with ELA response were 40.7%–57.9%. The most common adverse events were nasopharyngitis, folliculitis, upper respiratory tract infection, and urticaria. No serious or opportunistic infections, major adverse cardiovascular events, thromboembolic events, malignancies, or deaths were reported. Ritlecitinib demonstrated clinical efficacy and acceptable safety over 48 weeks in Asian patients ≥12 years with AA and ≥50% hair loss. Results for the Asian subpopulation were consistent with the overall population in the ALLEGRO-2b/3 study.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"603-614"},"PeriodicalIF":2.9,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17539","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous manifestations of Fabry disease: A systematic review","authors":"Rami Nabil Al-Chaer,&nbsp;Mathias Folkmann,&nbsp;Nina Løth Mårtensson,&nbsp;Ulla Feldt-Rasmussen,&nbsp;Mette Mogensen","doi":"10.1111/1346-8138.17690","DOIUrl":"10.1111/1346-8138.17690","url":null,"abstract":"<p>Fabry disease (FD) is a rare X-linked lysosomal storage disorder resulting in potential debilitating accumulation of glycosphingolipids in organs such as skin, nerves, heart, kidneys, lungs, and the central nervous system. Skin is easily investigated and can guide clinicians to diagnose FD, minimizing delay of enzyme substitution therapy. This systematic review followed the PICO and PRISMA guidelines. Using Web of Science, PubMed, and Embase, a total of 968 studies were retrieved by January 1, 2024. All clinical studies describing the skin characteristics and abnormalities of FD patients were included. After inclusion of articles, the methodological quality was assessed using the QUADAS-2 critical appraisal checklist. Twenty-three studies were included. Different skin manifestations were described in FD patients. Fifteen studies described angiokeratomas, five studied telangiectasias, 13 studied sweat abnormalities (anhidrosis/hypohidrosis/hyperhidrosis), nine described lymphoedema, and two reported hair abnormalities. Sweat abnormalities were the most common skin manifestation, affecting 57.6% of patients with FD; angiokeratomas were observed in 51.5% of patients. A high prevalence (16.5%) of lymphoedema was seen in a large study (<i>n</i> = 5487). Skin involvement appeared age-dependent and increased with age. Quality assessment showed high or unclear risk of bias in 19/23 studies. We summarized data on skin manifestations in 10 757 FD patients. The pathogenesis of sweat abnormalities and the occurrence of cutaneous vascular lesions, such as angiokeratomas and telangiectasias, in only half of FD patients remains poorly understood. Enzyme replacement therapy generally did not reduce skin manifestations in FD patients. Direct comparisons between studies were challenging due to variations in reported outcomes.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"571-582"},"PeriodicalIF":2.9,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17690","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of efficacy and adverse events by treatment cycles of nivolumab and ipilimumab in Japanese melanoma patients: A single-center, retrospective study","authors":"Ken Horisaki,&nbsp;Shusuke Yoshikawa,&nbsp;Wataru Omata,&nbsp;Arata Tsutsumida,&nbsp;Yoshio Kiyohara","doi":"10.1111/1346-8138.17672","DOIUrl":"10.1111/1346-8138.17672","url":null,"abstract":"<p>Combination therapy with nivolumab and ipilimumab (NIVO+IPI) is highly effective in treating advanced malignant melanoma (MM) but it is associated with a high incidence of treatment-related adverse events (TRAEs). This retrospective, cohort study evaluated the efficacy and TRAEs of NIVO+IPI in Japanese patients with unresectable stage III and IV MM, comparing outcomes based on the number of treatment cycles and the IPI dose. We reviewed data from 57 patients with advanced or recurrent MM who received NIVO+IPI at the Shizuoka Cancer Center between August 2015 and July 2024. Patients who received two or fewer NIVO + IPI cycles (NIVO+IPI ≤2 cycles) generally had worse Eastern Cooperative Oncology Group performance status and more advanced stages compared to those who received three or more cycles (NIVO+IPI ≥3 cycles). The analysis revealed that the NIVO+IPI ≥3 cycles group had significantly better overall survival compared to the NIVO+IPI ≤2 cycles group, although receiving three or more cycles was not an independent prognostic factor in multivariate analysis. There was no significant difference in the frequency or severity of TRAEs between the two groups, but the incidence of grade ≥3 TRAEs increased significantly between the first and second cycles of NIVO+IPI. Additionally, reducing the IPI dose from 3 mg/kg to 2 mg/kg appeared to lower the risk of grade ≥3 TRAEs. In conclusion, further research is needed to determine the optimal number of NIVO+IPI cycles for Japanese patients with advanced MM. However, assessing efficacy after the second cycle may help avoid unnecessary NIVO+IPI administration. Reducing the IPI dose to 2 mg/kg may also offer a safer treatment approach for these patients.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"651-662"},"PeriodicalIF":2.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17672","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143560529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A vulvar fibroadenoma: A rare presentation of ectopic breast tissue","authors":"Ramiro Alanis Ronquillo,&nbsp;Ixchel Kenia Martínez Velo,&nbsp;Erandy Alicia Salcedo Elguea,&nbsp;Gerardo Torres Barragán,&nbsp;Carmen Itzayana Rodríguez Chaparro","doi":"10.1111/1346-8138.17683","DOIUrl":"10.1111/1346-8138.17683","url":null,"abstract":"<p>A 39-year-old woman with a 4 × 4 cm vulvar mass of insidious growth, which increased in size over 16-years in relation to her menstrual cycles. The lesion had a polypoid appearance, regular borders, and firm consistency, and adhered to deep planes, without discoloration or collateral circulation. It was painful to palpation and movement (Figure 1). Histopathological examination after surgical resection reported a benign, biphasic neoplasm with an epithelial component showing ducts and papillae lined by cuboidal and cylindrical cells, without atypia. There was no evidence of necrosis or mitosis, which led to a diagnosis of vulvar fibroadenoma in ectopic mammary tissue (Figure 1).</p><p>Vulvar fibroadenoma is a rare benign tumor, with approximately 54 cases reported so far. The origin of these tumors has been the subject of debate, with two main theories. The first theory postulates that these tumors arise from ectopic breast tissue due to incomplete regression of the embryonic mammary line; the other theory suggests that they originate in the anogenital glands which are similar to the mammary glands.<span>^{1, 2}</span></p><p>Clinically, vulvar fibroadenomas typically present as painless, mobile masses in the vulvar region, often confused with cysts or other benign lesions.<span>²</span> Histopathological examination is essential for diagnosis, revealing the typical features of fibroadenoma, including a nodular overgrowth of epithelial and stromal components.<span>^{1, 3}</span> Because of the potential for malignant transformation, complete excision with clear margins and close follow-up is recommended.<span>³</span></p><p>Vulvar fibroadenoma is a rare occurrence in dermatology, presenting as a benign neoplasm that is more commonly associated with ectopic breast tissue. Given their rarity, these lesions can be misdiagnosed, especially if they show atypical features such as pseudolactational changes, which can mimic malignancy. It presents with non-specific symptoms or may be associated with hormonal changes. Diagnosis is supported by microscopic examination, and excision is the ideal treatment.</p><p>None declared.</p><p>Informed consent was obtained from the patient for publication of this case report.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"e264-e265"},"PeriodicalIF":2.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17683","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life of patients with pustular psoriasis is inferior to that of patients with plaque psoriasis in Japan: A multicenter study with questionnaires, the short Form-36, and other patient-reported outcomes","authors":"Shinichi Imafuku,&nbsp;Atsushi Satoh,&nbsp;Hisatomi Arima,&nbsp;Noriko Tsuruta,&nbsp;Ryoko Iwasaki,&nbsp;Hana Kimura,&nbsp;The Western Japan Inflammatory Skin Disease Research Group","doi":"10.1111/1346-8138.17629","DOIUrl":"10.1111/1346-8138.17629","url":null,"abstract":"<p>Generalized pustular psoriasis is a rare but severe form of psoriasis, accounting for 7.5% of all psoriasis cases. We investigated whether the disease burden and quality of life of patients with generalized pustular psoriasis were lower than those of patients with psoriasis vulgaris in Japan. Patients registered in the Western Japan Psoriasis Registry, a prospective cohort of patients with psoriasis treated at 31 facilities specializing in psoriasis medicine, were surveyed using the SF-36v2 and other patient-reported outcomes. We enrolled patients with generalized pustular psoriasis (<i>n</i> = 97) and psoriasis vulgaris (<i>n</i> = 1065). The generalized pustular psoriasis group had fewer males, were younger at onset, had fewer smokers and habitual drinkers, and were more frequently treated with biologics than patients with psoriasis vulgaris. Questions on disease burden revealed that patients with generalized pustular psoriasis experienced sores, blisters, skin pain, and systemic symptoms more frequently than patients with psoriasis vulgaris. A higher proportion of patients with generalized pustular psoriasis had joint pain and fatigue than those with psoriasis vulgaris, although patient satisfaction with treatment did not differ significantly between the two groups. The Short Form-36 evaluation revealed that patients with generalized pustular psoriasis had significantly lower physical component summary scores than patients with psoriasis vulgaris. These findings indicate that patients with generalized pustular psoriasis have a higher burden and more impaired quality of life than patients with psoriasis vulgaris.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"682-694"},"PeriodicalIF":2.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study","authors":"Yukari Okubo,&nbsp;Masamoto Murakami,&nbsp;Satomi Kobayashi,&nbsp;Shigeyoshi Tsuji,&nbsp;Mitsumasa Kishimoto,&nbsp;Kimitoshi Ikeda,&nbsp;Maiko Jibiki,&nbsp;Ezequiel Neimark,&nbsp;Byron Padilla,&nbsp;Jie Shen,&nbsp;Sydney Peters,&nbsp;Tadashi Terui","doi":"10.1111/1346-8138.17659","DOIUrl":"10.1111/1346-8138.17659","url":null,"abstract":"<p>Palmoplantar pustulosis (PPP) is a chronic, debilitating skin disease of the palms and/or soles. We report the efficacy and safety of risankizumab (RZB), an interleukin 23 p19 inhibitor, from the JumPPP study (a phase 3, multicenter, randomized, placebo-controlled, double-blind study to evaluate RZB in adult Japanese sUbjects with Moderate-to-severe PalmoPlantar Pustulosis; NCT04451720). Patients were randomized 1:1 to receive RZB (150 mg) or placebo at weeks 0 and 4; all patients received RZB from week 16 to week 52 (patients initially randomized to RZB) or week 56 (patients initially randomized to placebo). The primary end point was a Palmoplantar Pustulosis Area and Severity Index (PPPASI) change from baseline; secondary end points were ≥50%/≥75% improvement in PPPASI (PPPASI 50/75) at week 16. Efficacy and safety were evaluated to 68 and 76 weeks, respectively. In total, 119 patients (RZB, <i>n</i> = 61; placebo, <i>n</i> = 58) were enrolled. Greater improvement with RZB versus placebo was demonstrated by the significant difference in PPPASI change from baseline at week 16 (least squares mean treatment difference, −3.48; <i>p</i> &lt; 0.05). At week 16, a greater proportion of patients receiving RZB vs placebo achieved PPPASI 50 (41.0% vs 24.1%; nominal <i>p</i> &lt; 0.05) but not PPPASI 75 (13.1% vs 15.5%; nominal <i>p</i> = 0.74). Improvements generally continued through to week 68. The safety profile was generally consistent with previous studies of RZB in psoriasis. RZB demonstrated efficacy over placebo at week 16 in Japanese patients with PPP, with improvements sustained through to week 68, and was well tolerated with no unexpected safety findings.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"593-602"},"PeriodicalIF":2.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17659","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perspectives and history in genodermatoses","authors":"Akiharu Kubo","doi":"10.1111/1346-8138.17657","DOIUrl":"10.1111/1346-8138.17657","url":null,"abstract":"<p>Advances in next-generation sequencing have facilitated the identification of disease-associated genes for a significant proportion of genetic skin diseases, thereby integrating genetic diagnosis into standard medical care. In Japan, the list of genetic diseases for which genetic diagnosis is available under national health insurance is expanding every year. Since misinterpretation of results of genetic analyses can lead to incorrect genetic counseling, the need for physicians to have a thorough knowledge of genetics is growing massively.</p><p>A common challenge in genetic diagnosis is determining whether multiple heterozygous variations detected in the proband are restricted to a single allele or are present in different alleles. This challenge is called “phasing” and typically arises when genomic DNA from the proband's parents is not available. Natsuga presents a comprehensive review of phasing, a critical method for addressing this challenge.</p><p>It is becoming clear that a variety of genetic factors underlie common diseases such as atopic dermatitis and psoriasis. Akiyama provides an update on the genetic basis of pustular psoriasis, which is thought to have a particularly strong genetic component associated with inflammatory responses.</p><p>There are still some rare diseases for which the genetic cause has not been identified, even with the latest various genetic analysis methods, including next-generation sequencing. To identify a novel disease and a novel genetic, epigenetic or yet unknown genomic cause, it is necessary to accumulate as many cases of the disease as possible. For this purpose, careful description of skin lesions by descriptive dermatology and systematic search for analogous cases is important. Kubo described the history of the discovery of Nagashima-type palmoplantar keratosis from the identification of the disease to the identification of the disease-causing variants in SERPINB7. This record will be useful for future attempts to identify a new independent disease and its pathogenetic factors.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 3","pages":"391"},"PeriodicalIF":2.9,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17657","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravenous immunoglobulin inhibits neutrophil extracellular traps in Stevens-Johnson syndrome/toxic epidermal necrolysis","authors":"Manao Kinoshita,&nbsp;Youichi Ogawa,&nbsp;Shinji Shimada,&nbsp;Riichiro Abe,&nbsp;Tatsuyoshi Kawamura","doi":"10.1111/1346-8138.17675","DOIUrl":"10.1111/1346-8138.17675","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 3","pages":"565-566"},"PeriodicalIF":2.9,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudy","authors":"Nicoline F. van Buchem-Post,&nbsp;Wouter Ouwerkerk,&nbsp;Eileen W. Stalman,&nbsp;Koos P. J. van Dam,&nbsp;Luuk Wieske,&nbsp;Marcel W. Bekkenk,&nbsp;Albert Wolkerstorfer,&nbsp;Phyllis Spuls,&nbsp;Annelie H. Musters,&nbsp;Angela L. Bosma,&nbsp;Dirk-Jan Hijnen,&nbsp;Filip Eftimov,&nbsp;Rosalie M. Luiten,&nbsp;T2B! immunity against SARS-CoV-2 study group,&nbsp;Zoé L. E. van Kempen,&nbsp;Eileen W. Stalman,&nbsp;Maurice Steenhuis,&nbsp;Laura Y. L. Kummer,&nbsp;Koos P. J. van Dam,&nbsp;Anja Ten Brinke,&nbsp;S. Marieke van Ham,&nbsp;Taco Kuijpers,&nbsp;Theo Rispens,&nbsp;Filip Eftimov,&nbsp;Luuk Wieske,&nbsp;Joep Killestein,&nbsp;A. J. Vd Kooi,&nbsp;J. Raaphorst,&nbsp;A. H. Koos Zwinderman,&nbsp;M. Löwenberg,&nbsp;A. G. Volkers,&nbsp;G. R. A. M. D'Haens,&nbsp;R. B. Takkenberg,&nbsp;S. W. Tas,&nbsp;M. L. Hilhorst,&nbsp;Y. Vegting,&nbsp;F. J. Bemelman,&nbsp;N. J. M. Verstegen,&nbsp;L. Fernandez,&nbsp;S. Keijzer,&nbsp;J. B. D. Keijser,&nbsp;O. Cristianawati,&nbsp;A. E. Voskuyl,&nbsp;B. Broens,&nbsp;A. P. Sanchez,&nbsp;S. Nejentsev,&nbsp;E. S. Mirfazeli,&nbsp;G. J. Wolbink,&nbsp;L. Boekel,&nbsp;B. A. Rutgers,&nbsp;K. de Leeuw,&nbsp;B. Horváth,&nbsp;J. J. G. M. Verschuuren,&nbsp;A. M. Ruiter,&nbsp;L. van Ouwerkerk,&nbsp;D. van der Woude,&nbsp;Rcf Allaart,&nbsp;Yko Teng,&nbsp;M. H. Busch,&nbsp;E. Brusse,&nbsp;P. A. van Doorn,&nbsp;Mae Baars,&nbsp;Crg Schreurs,&nbsp;W. L. van der Pol,&nbsp;H. S. Goedee,&nbsp;C. A. C. M. van Els,&nbsp;J. de Wit","doi":"10.1111/1346-8138.17664","DOIUrl":"10.1111/1346-8138.17664","url":null,"abstract":"<p>During the COVID-19 pandemic, the daily life of many patients with dermatological immune-mediated inflammatory diseases (DIMIDs), such as atopic dermatitis (AD), psoriasis, and vitiligo, was impacted by social restrictions caused by (fear of) morbidity, mortality associated with COVID-19, and vaccine hesitancy. This prospective observational, multicenter, multidisciplinary cohort study explored the impact of COVID-19 disease and vaccination on DIMIDs, specifically AD, psoriasis, and vitiligo. Data from patients with DIMIDs were collected as part of the Target2B! study (between February 2021 and October 2022). We analyzed the differences in baseline characteristics, risk of developing COVID-19, proportion of DIMIDs in patients reaching seroconversion upon vaccination per DIMID, and self-reported increase in DIMID activity by multivariable logistic regression and sensitivity analyses. A total of 424 patients with DIMID were included. COVID-19 disease commonly occurred in patients with vitiligo (51.1%), AD (42.0%), and psoriasis (34.3%) (<i>p</i> = 0.038). COVID-19 was not associated with the use of immunosuppressive therapy. Three patients (two with AD and one with vitiligo) were hospitalized due to COVID-19. Nearly all patients with DIMIDs exhibited effective seroconversion after regular vaccination regimens (vitiligo 100%, psoriasis 97.9%, AD 96.5%). Increased DIMID activity after COVID-19 (6.6%) or severe acute respiratory syndrome–related coronavirus (SARS-CoV-2) vaccination (12.26%) was reported in a minority of patients, with baseline progressive disease (disease activity 3 months preceding baseline survey) being the only associated risk factor (COVID-19: odds ratio [OR], 4.27 [<i>p</i> = 0.02]; vaccination OR, 3.45 [<i>p</i> = 0.002]). In conclusion, no alarming signs were shown in this study regarding (severe) COVID-19 in patients with AD, psoriasis, or vitiligo. Vaccination against COVID-19 is advised in patients with DIMIDs. Moreover, patients with DIMIDs can safely continue their immunosuppressant therapy, since this does not increase the risk of COVID-19, while vaccination-induced humoral responses are adequate. In only a minority of patients, increased DIMID activity after COVID-19 or SARS-CoV-2 vaccination occurred.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"52 4","pages":"624-633"},"PeriodicalIF":2.9,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17664","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}